Your Health, We Care
Balversa has been approved in the United States and multiple other countries for the treatment of eligible patients with urothelial carcinoma. As the first FDA approved oral FGFR inhibitor, edatinib holds significant importance in the field of cancer treatment.
Balversais an oral anticancer drug targeting FGFR mutations for the treatment of specific types of cancer, such as urothelial carcinoma, and provides patients with new therapeutic ···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：99
Balversais a new oral anti-cancer drug targeting FGFR, which is specially designed for cancer patients with FGFR gene mutations, precisely inhibiting tumor growth, and providing ne···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：113
Balversais an oral tyrosine kinase inhibitor for the treatment of non-small cell lung cancer and urothelial carcinoma, among others, and provides a new treatment option for patient···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：109
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
